A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects

NACompletedINTERVENTIONAL
Enrollment

1,206

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions
Influenza
Interventions
BIOLOGICAL

Vaccination with FAB-6011

One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.

BIOLOGICAL

Vaccination with FluvalAB

One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.

Trial Locations (7)

1083

Family Doctor's Office, Budapest

1136

Family Doctor's Office, Budapest

2000

Family Doctor's Office, Szentendre

2051

Péter Vajer, Biatorbágy

2085

Family Doctor's Office, Pilisvörösvár

2220

Tibor Hrutka, Vecsés

3000

Barna Bőze, Hatvan

All Listed Sponsors
lead

Fluart Innovative Vaccine Ltd, Hungary

INDUSTRY